



November 15, 2019

Novartis Pharma AG  
CH-4002, Basel, Switzerland

Reference: EudraCT 2012-003348-63/ Novartis Protocol ID CBPS804A2204

A randomized, placebo-controlled trial of BPS804 on safety and tolerability in patients with late-stage chronic kidney disease

Trial CBPS804A2204 was cancelled with no patient enrollment and as such, no results will be reported.

Due to a flaw in the EudraCT system, the Global End of Trial date in the system only was changed to July 1, 2012 to allow upload of this letter to notify the public that this trial was cancelled and no patients were enrolled.